Longeveron Inc. Files 8-K for FY 2024 Results
Ticker: LGVN · Form: 8-K · Filed: Feb 28, 2025 · CIK: 1721484
Sentiment: neutral
Topics: financial-results, 8-k, pharmaceutical
TL;DR
Longeveron dropped its 2024 year-end financials. Check it out.
AI Summary
Longeveron Inc. filed an 8-K on February 28, 2025, reporting its financial results for the fiscal year ending December 31, 2024. The filing details the company's operational and financial condition for the period.
Why It Matters
This filing provides investors with the official financial performance and operational status of Longeveron Inc. for the fiscal year 2024, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Longeveron faces inherent risks related to drug development, regulatory approvals, and market competition, which are reflected in its financial reporting.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for financial results)
Key Players & Entities
- Longeveron Inc. (company) — Registrant
- December 31, 2024 (date) — Fiscal Year End
- February 28, 2025 (date) — Filing Date
- Miami, Florida (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report Longeveron Inc.'s results of operations and financial condition for the fiscal year ending December 31, 2024.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on February 28, 2025.
What is Longeveron Inc.'s principal executive office address?
Longeveron Inc.'s principal executive office is located at 1951 NW 7th Avenue, Suite 520, Miami, Florida 33136.
What is the Commission File Number for Longeveron Inc.?
The Commission File Number for Longeveron Inc. is 001-40060.
What is the SIC code for Longeveron Inc.?
The Standard Industrial Classification (SIC) code for Longeveron Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 28, 2025 regarding Longeveron Inc. (LGVN).